Dit is de originele tekst: er zijn geen institutionele beleggers:
-----------------------------------------------------------------
Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 27, 2018, 18:30 CEST. - Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has obtained commitments from qualified investors in Europe and the United States to subscribe for 854,166 new ordinary shares (the “Offer Shares”) of the Company (the “Offering”).
Total gross proceeds from the Offering for the Company are expected to be EUR 4.1 million, before deducting fees and expenses.
The Company also secured an additional USD 10 million equity facility offered by Global Corporate Finance (GCF), New York, NY, USA, allowing the Company solely at its request to raise additional equity over a period of up to 36 months subject to certain pre-agreed floor pricing.